Mechanism(s) of interferon inhibitory activity in blood from patients with aids and patients with lupus erythematosus with vasculitis

Research Communications in Molecular Pathology and Pharmacology

Volumn 96, Issue 3, 1997, Pages 255-265

  Ambrus, Julian L ^a,d   Ambrus Jr , Julian L ^a   Chadha, Sunita ^a   Novick, Daniela ^b   Rubinstein, Menachem ^b   Gopalakrishnan, Bhaskar ^c   Bernstein, Zale ^c   Priore, Roger L ^c   Chadha, Kailash C ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; INTERFERON; PROSTAGLANDIN E2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; WEGENER GRANULOMATOSIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBODIES; DINOPROSTONE; FEMALE; HUMANS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RECEPTORS, INTERFERON; VASCULITIS;

EID: 0030857195     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ambrus, JL, Ambrus, JL Jr, and Chadha, KC. (1986).: Interferon inhibitors in lupus erythematosus. N. Engl. J. Med. 319: 582-583.
2. Ambrus, JL, Chadha, KC, and Ambrus, JL Jr. (1991).: Interferon inhibitors in Wegner's granulomatosis. Ann. Intern. Med. 114: 606-607.
3. Ambrus, JL, Poiesz, BJ, Lillie, MA, Stadler, S, DiBernardino, L, and Chadha, KC. (1989).: Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, AIDS, ARC, Kaposi's sarcoma and in normal individuals. Amer. J. Med. 87: 405-407.
4. 2 and cAMP phosphodiesterase levels in Kaposi's sarcoma. Res. Comm. Chem. Pathol. Pharmacol. 78: 249-252..
5. 2 production by human tumors. Defense mechanism against the host? Res Comm. Chem. Pathol. Pharmacol. 43: 195-201.
6. Chadha, KC, Ambrus, JL, and Ikossi, MG. (1987).: Interferons and interferon inactivators in AIDS, ARC and in cancer patients. In: The Biology of the Interferon System, 1986. Edited by Cantell, K, Schellekens, H. Proc. of the 1986 ISIR-TNO Meeting on the Interferon System September 7-12, 1986 Espo Finland pp 423-427.
7. Chadha, KC, Ambrus, JL, Stadler, S. and Ambru, JL Jr. (1991).: Interferon inhibitor in the blood of patients with systemic lupus erythematosus. J. Biol. Regulat. Homeost. Agent. 4: 22-30.
8. Diez-Ruiz, A, Tilz, GP, Zangerle, R, Baier-Bitterlich, Wachter, G, and Fuchs, D. (1995).: Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 54: 1.
9. Gaillard, JP, Bataille, R, Brailly, H, Zuber, C, Yasukawa, K, Attal, M, Marno, N, Taga, T, Kishimoto, T, and Klein, B. (1993).: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol. 23: 820.
10. Hanneken, A, Ying, W, Ling, N, and Baird, A. (1994): Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc. Natl. Acad. Sci. USA 91: 9170-9174.
11. Novick, D, Cohen, B, Rubinstein, M. (1992).: Soluble interferon-α receptor molecules are present in body fluids. Fed. Eur. Biochem. Soc. 314: 445-448.
12. Novick, D, Cohen, B, and Rubinstein, M. (1994).: The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77: 391-397.
13. Novick, D, Engelmann, H, Wallach, D, Leitner, O, Revel, M, and Rubinstein, M. (1990).: Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr. 510: 331-337.
14. Novick, D, Engelmann, H, Wallach, D, and Rubinstein, M. (1989).: Soluble-cytokine receptors are present in normal human urine. J. Exp. Med. 170: 1409-1414.
15. O'Connor, MGI, Ambrus, JL, and Chadha, KC. (1986).: Regulation of in vitro human leukocyte interferon production: Effect of prostaglandin syntheses and phosphodiesterase inhibition. Res. Commun. Chem. Pathol. Pharmacol. 54: 379-384.
16. O'Connor, MGI, Chadha, KC, Lillie, MA, Bernstein, Z, Zucker-Franklin, D, and Ambrus, JL. (1986).: Interferon inactivation(s) in patients with AIDS and AIDS related Kaposi's sarcoma. Amer. J. of Med. 81: 738-786.
17. Ozman, L, Gribaudo, G, Fountoulakis, M, Gentz, R. Landolfo, S, and Garotta, G. (1991).: Mouse soluble IFN-γ inhibitor. J. Immunol. 150: 2698-2705.
18. Peetre, G, Thysell H, Grubb, A, and Olsson, I. (1988).: A tumor necrosis factor binding protein in human biological fluids. Eur. J. Hematol. 41: 414.
19. Spinas, GA, Keller, U, and Brockhaus, M. (1992).: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental exdotoxemia. J. Clin. Invest. 90: 533-539.
20. Stadler, S, Chadha, KC, Nakeeb, S, Toumbis, C, Butsch, J, Mathur, N, Munschaur, F, Vladutiu, A, and Ambrus, JL. (1994).: Pentoxifyline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. J. Pharmacol. Exp. Ther. 268 (1): 10-13.
21. Stefanovich, V, Ambrus, JL, Ambrus, CM, and Karakousis, CP, and Takita, H. (1981).: Cyclic nucleotide phosphodiesterases in normal and malignant human tissues. J. Med. 12: 243-250.
22. Zoon, KC and Arnheiter, F. (1984).: Studies of interferon receptors. Pharmacotherapy, 24: 239-278.